CRL
Price
$186.52
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
8 days until earnings call
PACB
Price
$1.84
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
9 days until earnings call
Ad is loading...

CRL vs PACB

Header iconCRL vs PACB Comparison
Open Charts CRL vs PACBBanner chart's image
Charles River Laboratories International
Price$186.52
Change-$0.00 (-0.00%)
Volume$506.52K
CapitalizationN/A
Pacific Biosciences of California
Price$1.84
Change-$0.00 (-0.00%)
Volume$6.22M
CapitalizationN/A
View a ticker or compare two or three
CRL vs PACB Comparison Chart
Loading...
CRL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CRL vs. PACB commentary
Oct 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRL is a Buy and PACB is a Buy.

COMPARISON
Comparison
Oct 30, 2024
Stock price -- (CRL: $186.52 vs. PACB: $1.84)
Brand notoriety: CRL and PACB are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CRL: 77% vs. PACB: 78%
Market capitalization -- CRL: $13.96B vs. PACB: $976.68M
CRL [@Medical Specialties] is valued at $13.96B. PACB’s [@Medical Specialties] market capitalization is $976.68M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRL’s FA Score shows that 0 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • CRL’s FA Score: 0 green, 5 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, CRL is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRL’s TA Score shows that 3 TA indicator(s) are bullish while PACB’s TA Score has 3 bullish TA indicator(s).

  • CRL’s TA Score: 3 bullish, 5 bearish.
  • PACB’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, PACB is a better buy in the short-term than CRL.

Price Growth

CRL (@Medical Specialties) experienced а -4.37% price change this week, while PACB (@Medical Specialties) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.01%. For the same industry, the average monthly price growth was +3.93%, and the average quarterly price growth was -2.96%.

Reported Earning Dates

CRL is expected to report earnings on Feb 12, 2025.

PACB is expected to report earnings on Feb 13, 2025.

Industries' Descriptions

@Medical Specialties (-2.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRL($14B) has a higher market cap than PACB($977M). CRL YTD gains are higher at: -21.100 vs. PACB (-81.244). CRL has higher annual earnings (EBITDA): 1.03B vs. PACB (-277.28M). PACB has more cash in the bank: 631M vs. CRL (277M). PACB has less debt than CRL: PACB (934M) vs CRL (3.07B). CRL has higher revenues than PACB: CRL (4.13B) vs PACB (201M).
CRLPACBCRL / PACB
Capitalization14B977M1,433%
EBITDA1.03B-277.28M-372%
Gain YTD-21.100-81.24426%
P/E Ratio29.15N/A-
Revenue4.13B201M2,054%
Total Cash277M631M44%
Total Debt3.07B934M328%
FUNDAMENTALS RATINGS
CRL vs PACB: Fundamental Ratings
CRL
PACB
OUTLOOK RATING
1..100
568
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
6298
PRICE GROWTH RATING
1..100
6361
P/E GROWTH RATING
1..100
5084
SEASONALITY SCORE
1..100
2195

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRL's Valuation (74) in the Miscellaneous Commercial Services industry is in the same range as PACB (99) in the Biotechnology industry. This means that CRL’s stock grew similarly to PACB’s over the last 12 months.

CRL's Profit vs Risk Rating (77) in the Miscellaneous Commercial Services industry is in the same range as PACB (100) in the Biotechnology industry. This means that CRL’s stock grew similarly to PACB’s over the last 12 months.

CRL's SMR Rating (62) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for PACB (98) in the Biotechnology industry. This means that CRL’s stock grew somewhat faster than PACB’s over the last 12 months.

PACB's Price Growth Rating (61) in the Biotechnology industry is in the same range as CRL (63) in the Miscellaneous Commercial Services industry. This means that PACB’s stock grew similarly to CRL’s over the last 12 months.

CRL's P/E Growth Rating (50) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for PACB (84) in the Biotechnology industry. This means that CRL’s stock grew somewhat faster than PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRLPACB
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 13 days ago
73%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
65%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Ad is loading...
CRL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.732.16
+10.50%
GameStop Corp
BTC.X69907.7600001978.460900
+2.91%
Bitcoin cryptocurrency
AAPL233.401.99
+0.86%
Apple
SPY580.831.79
+0.31%
SPDR® S&P 500® ETF Trust
TSLA262.51-6.68
-2.48%
Tesla

CRL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRL has been closely correlated with IQV. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRL jumps, then IQV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRL
1D Price
Change %
CRL100%
+2.42%
IQV - CRL
75%
Closely correlated
+1.36%
AZTA - CRL
65%
Loosely correlated
+2.54%
TMO - CRL
59%
Loosely correlated
-0.33%
WAT - CRL
57%
Loosely correlated
+0.30%
DHR - CRL
57%
Loosely correlated
-0.52%
More

PACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
+3.95%
MASI - PACB
58%
Loosely correlated
+0.99%
AZTA - PACB
48%
Loosely correlated
+2.54%
TWST - PACB
43%
Loosely correlated
+4.73%
MASS - PACB
41%
Loosely correlated
+3.04%
VCYT - PACB
40%
Loosely correlated
+3.30%
More